Want to see SLDB full AI Analyst Report?
SLDB Stock Chart & Stats
$9.89
-$0.15(-1.88%)
At close: 4:00 PM EDT
$9.89
-$0.15(-1.88%)
Day’s Range― - ―
52-Week Range$3.79 - $11.45
Previous CloseN/A
Volume1.09M
Average Volume (3M)925.52K
Market Cap
$1.03B
Enterprise Value$1.08K
Total Cash (Recent Filing)$377.68M
Total Debt (Recent Filing)$20.16M
Price to Earnings (P/E)―
Beta1.71
Next Earnings
Nov 11, 2026EPS Estimate
-0.41Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.91
Shares Outstanding107,225,235
10 Day Avg. Volume892,146
30 Day Avg. Volume925,519
Financial Highlights & Ratios
PEG Ratio0.08
Price to Book (P/B)2.74
Price to Sales (P/S)0.00
P/FCF Ratio-3.13
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$19.17Price Target Upside93.80% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)-1.76
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Balance-sheet LeverageModest leverage limits fixed financial obligations and provides greater flexibility to fund clinical programs. However, this strength is partly offset by ongoing losses and the possibility that future capital needs require equity issuance.
Focused Genetic-medicine PlatformA focused genetic-medicine strategy can build specialized capabilities, clinical expertise and platform knowledge across related diseases. These capabilities may support multiple development opportunities, although value creation remains dependent on clinical and regulatory execution.
Expanded Financing FlexibilityAccess to a substantial equity facility can extend development funding and reduce near-term financing constraints for clinical programs. It also gives management flexibility to respond to milestones, but the benefit depends on disciplined capital deployment.
Bears Say
No Current Commercial RevenueThe absence of recurring product revenue leaves the company dependent on clinical success, partnerships or future approvals to establish a commercial funding base. Widening losses indicate that operating scale has not yet offset development costs.
Severe And Worsening Cash BurnLarge negative operating and free cash flow increases reliance on external capital and makes financial sustainability sensitive to trial spending, timing and financing conditions. Unless revenue emerges or costs moderate, recurring funding needs may persist.
Structural Dilution RiskExpanded share authorization and available equity programs improve funding capacity but create a durable risk of ownership dilution. Repeated issuance could reduce each existing shareholder's proportional participation in future clinical or commercial value.
Solid Biosciences News
SLDB FAQ
What was Solid Biosciences’s price range in the past 12 months?
Solid Biosciences lowest stock price was $3.79 and its highest was $11.45 in the past 12 months.
What is Solid Biosciences’s market cap?
Solid Biosciences’s market cap is $1.03B.
When is Solid Biosciences’s upcoming earnings report date?
Solid Biosciences’s upcoming earnings report date is Nov 11, 2026 which is in 70 days.
How were Solid Biosciences’s earnings last quarter?
Solid Biosciences released its earnings results on Aug 06, 2026. The company reported -$0.38 earnings per share for the quarter, beating the consensus estimate of -$0.462 by $0.082.
Is Solid Biosciences overvalued?
According to Wall Street analysts Solid Biosciences’s price is currently Undervalued.
Does Solid Biosciences pay dividends?
Solid Biosciences does not currently pay dividends.
What is Solid Biosciences’s EPS estimate?
Solid Biosciences’s EPS estimate is -0.41.
How many shares outstanding does Solid Biosciences have?
Solid Biosciences has 107,225,235 shares outstanding.
What happened to Solid Biosciences’s price movement after its last earnings report?
Solid Biosciences reported an EPS of -$0.38 in its last earnings report, beating expectations of -$0.462. Following the earnings report the stock price went down -3.674%.
Which hedge fund is a major shareholder of Solid Biosciences?
Currently, no hedge funds are holding shares in SLDB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Solid Biosciences Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$19.17 (93.80% Upside)
$19.17 (93.80% Upside)
Blogger Sentiment
Bullish
SLDB Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 3.2M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Negative
Last 7 Days ▼ 0.1%
Last 30 Days ▼ 0.6%
Last 30 Days ▼ 0.6%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
80.29%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
36.42%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Solid Biosciences
Solid Biosciences Inc. is an American biotechnology firm dedicated to creating therapeutic solutions for Duchenne Muscular Dystrophy (DMD). Its most advanced experimental drug, SGT-001, is a gene transfer treatment currently in Phase I/II clinical trials, designed to encourage the production of functional dystrophin protein in patients' muscles. The company is also progressing with SGT-003, which represents a next-generation gene transfer therapy intended for DMD. Beyond specific drug candidates, Solid Biosciences is actively developing innovative platform technologies, such as "dual gene expression," a technique that allows for multiple therapeutic genes to be bundled into a single viral vector, and researching new capsid designs. The company maintains a strategic alliance through a collaboration and license agreement with Ultragenyx Pharmaceutical Inc., focusing on the joint development and market introduction of novel gene therapies for Duchenne Muscular Dystrophy. Founded in 2013, Solid Biosciences Inc. conducts its operations from its headquarters in Cambridge, Massachusetts.
SLDB Stock 12 Month Forecast
Average Price Target
$19.17
▲(93.80% Upside)
Technical Analysis
Ownership Overview
12.09% Insiders
9.98% Mutual Funds
62.60% Other Institutional Investors
2.77% Public Companies and
Individual Investors